Generation of TCR-mimic antibodies targeting intracellular proteins to expand the druggable target repertoire for anti-tumor therapies
Speaker: W. Frank An, PhD.
Sr. Director of Antibody Therapeutics, Biocytogen Institute for Therapeutic Innovations, Biocytogen Pharmaceuticals
Traditional antibody therapy has been limited to extracellular tumor targets; however, many oncogenic and tumor-associated proteins are intracellular. One strategy to overcome this limitation is to target the pHLA complex mimicking TCR recognition. In this webinar, Dr. W. Frank An outlined the current progress in the field of TCR-mimic(TCRm) antibody discovery, highlighting Biocytogen’s lead TCRm programs, which have generated highly specific antibodies for bispecific engager therapy and TCRm-T cell therapy.